|
| Study | Study type | Total patients | Follow-up duration | Treatment regimen | Treatment duration | Efficacy assessment | Region |
|
| Blauvelt et al. [9] | CT | 348 | February 21, 2019, to December 9, 2020 | Once-daily upadacitinib 30 mg | 24 weeks | EASI | 129 centers located in 22 countries across Europe, North and South America, Oceania, and the Asia-Pacific region |
| NRS |
|
| Guttman-Yassky et al. [19] | CT | 126
Group 1: 42
Group 2: 42
Group 3: 42 | November 21, 2016, to April 20, 2017 | Once-daily upadacitinib oral monotherapy
Group 1: 7.5 mg
Group 2: 15 mg
Group 3: 30 mg | 16 weeks | EASI | Australia, Canada, Finland, Germany, Japan, the Netherlands, Spain, and the United States |
| IGA |
| NRS |
| SCORAD |
| BSA |
| POEM |
|
Guttman-Yassky et al. [19]
(Measure up 1) | CT | 566
Group 1: 281
Group 2: 285 | August 13, 2018, to December 23, 2019 | Once-daily upadacitinib oral monotherapy
Group 1: 15 mg
Group 2: 30 mg | 16 weeks | EASI and IGA | 151 clinical centers in 24 countries across Europe, North and South America, Oceania, and the Asia-Pacific region |
| WP-NRS |
| ADerm-IS, ADerm-SS |
| POEM |
| HADS |
| DLQI |
|
Guttman-Yassky et al. [19]
(Measure up 2) | CT | 558
Group 1: 276
Group 2: 282 | July 27, 2018, to January 17, 2020 | Once-daily upadacitinib oral monotherapy
Group 1: 15 mg
Group 2: 30 mg | 16 weeks | EASI and IGA | 54 clinical centers in 23 countries across Europe, North America, Oceania, and the Asia-Pacific region |
| WP-NRS |
| ADerm-IS, ADerm-SS |
| POEM |
| HADS |
| DLQI |
|
| Katoh et al. [20] | CT | 182
Group 1: 91
Group 2: 91 | From November 17, 2018 | Once-daily upadacitinib oral with medium-potency topical corticosteroids (TCSs)
Group 1: 15 mg
Group 2: 30 mg | 24 weeks | EASI and IGA | Japan |
| NRS |
|
| Chiricozzi et al. [24] | OS, P | 43 | October 2020 to June 2021 | Once-daily upadacitinib 30 mg | 16 weeks | EASI | Italy |
| BSA |
| NRS |
| DLQI |
| POEM |
|
| Bello et al. [27] | CS, R | 10 | NR | Mostly upadacitinib 15 mg | 8 weeks | EASI and NRS | Italy |
|
| Hagino et al. [23] | OS, R | 31 | September 2021 to March 2022 | Once-daily 15 mg upadacitinib oral with plus twice daily topical corticosteroids of medium to strongest classes | 12 weeks | EASI | Japan |
| IGA |
| ADCT |
| NRS |
|
| Pereyra-Rodriguez et al. [25] | OS, R | 43 | October 2020 to March 2022 | Mostly once-daily upadacitinib 30 mg (60%) | 16 weeks | SCORAD | Spain |
| EASI |
| DLQI |
| NRS |
| BSA |
| IGA |
|
| Napolitano et al. [28] | OS, R | 9 | From June 2021 | Once-daily upadacitinib 30 mg | 16 weeks | EASI | Italy |
| DLQI |
| NRS |
|
| Feraru et al. [26] | CS, R | 12 | July 2020 to November 2021 | Once-daily upadacitinib 30 mg or 15 mg | 24 weeks | vIGA | Israel |
|
